Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Proven Benefits
The STEP trial program examining higher-dose semaglutide (2.4 mg weekly) for weight management demonstrated mean weight loss of 12% to 15% over 68 weeks in adults with obesity, significantly exceeding placebo
Gilmartin J
Shared decision-making ensures that your treatment plan aligns with your goals, preferences, and individual medical circumstances
Thirdly, the objective of treating obesity extends beyond weight loss to include the prevention of obesity-related complications and improvements in comorbid conditions, as evidenced by positive changes in cardiometabolic risk factors observed in Phase 3 clinical trials [87]
US$ 23.02
US$ 28.23
US$ 23.23
US$ 20.87
US$ 25.37
US$ 29.75
US$ 27.37
US$ 22.32
US$ 29.62
US$ 25.86
